Clinical Trial Update: JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating JK-1201I in patients with triple-negative breast cancer and brain metastases; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Triple-negative Breast Cancer

Drugs mentioned

• JK-1201I

Snippet

Sponsor: JenKem Technology Co., Ltd. | Conditions: Triple Negative Breast Cancer (TNBC), Brain Metastasases | Phase 2 | Status: NOT_YET_RECRUITING